Amgen’s (AMGN) stock outperformed in the past 6 months for significant reasons and these reasons are still there as we observed listening to the firm’s quarterly results. The firm’s results surpassed analysts’ expectations. The stock outperformed because the firm outperformed, never letting its accomplishments emanate from the past successes, but through updating its technologies and products to where the scientific knowledge has reached.

That’s the reason why in the report Amgen had to update its guidance. The updates comprised:

Total product sales increase of 2 percent for the second quarter of 2017 . . .